Abstract
Background Morphine is one of the oldest, most commonly prescribed, and widely used opioids in the United States (US). Morphine’s potent analgesic properties have also been associated with the increase in misuse, addiction and opioid-related deaths in the US since the 1990s. Despite federal regulations, population-adjusted prescription opioid distribution varies markedly between states. The objective of this study was to describe the temporal pattern of morphine distribution nationally and between states.
Methods Drug weight and population data were obtained from Report 5 of the US Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS) to characterize patterns in the distribution of morphine from 2012 to 2020.
Morphine distribution amounts were separated by state and business type and corrected for population. States outside a 95% confidence interval relative to the national average were considered statistically significant.
Results Pharmacies and hospitals distributed 24,200 kilograms of morphine in 2012. Tennessee (180.2 mg/person) was 4.7-fold higher than Texas (39.4 mg/person).
National distribution decreased 56.4% to 10,723 kilograms in 2020. Tennessee (56.4 mg/person) was 3.8-fold higher than the District of Columbia (15.0 mg/person). The decline in Illinois (−40.9%) was significantly less than the national average (−56.8%) while that of Oregon (−71.1%) and Arizona (−70.4%) were significantly higher. Hospital decrease (−72.7%) from 2012-2020 was larger than that of pharmacies (−56.12%).
Conclusions The national 56% decline in the distribution of morphine in the last decade may be attributable to prioritization of the opioid crisis as a public concern, including subsequent growth of opioid misuse and treatment programs and decreased production quotas for opioids, including morphine. This decline also coincides with the national shortage of parenteral opioids resulting in greater prescriptions of alternative opioids such as nalbuphine and buprenorphine. Further research is necessary to understand the persistent four-fold regional difference between states.
Competing Interest Statement
BJP was (2019-2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Funding Statement
This study did not receive any external funding. Publication costs may be paid for by Geisinger Commonwealth School of Medicine. BJP is supported by the Health Resources Services Administration (D34HP31025).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available data that were originally located: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: BJP was (2019-2021) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. The other authors have no disclosures.
Data Availability
Raw data is available at: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html